Saskia Gruber

Dr. Saskia Gruber

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in Vaccine
Verified
Journal Article
Closed access
MPMartina Prelog
Martina Prelog
JSJörn Schönlaub
Jörn Schönlaub
VJVerena Jeller
Verena Jeller
GAGiovanni Almanzar
Giovanni Almanzar
KHKerstin Höfner
Kerstin Höfner
RWReinhard Würzner
Reinhard Würzner

16 October 2012 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
PDF file
TEThomas Eiwegger
Thomas Eiwegger
SGSaskia Gruber
Saskia Gruber
ZSZsolt Szepfalusi
Zsolt Szepfalusi
CACezmi A. Akdis
Cezmi A. Akdis
Allergy is the result of a disbalanced immune response to environmental innocuous antigens. Despite of accumulating data to define the pathomechanisms that take place in case of allergic diseases a detailed understanding of sequence of events that lead to the "normal" scenario of tolerance development are still under debate. Allergen-specific immunotherapy is the only causal treatment of allergic diseases. It modifies the immune response to a particular antigen to achieve tolerance against the symptom-causing allergen. This process is considered to mirror physiological peripheral tolerance induction. A number of immunological changes have been described to occur under allergen immunotherapy, including the generation of allergen-specific regulatory T cells, the induction of allergen-specific IgG4, an increase in the Th1/Th2 cytokine ratio and decreased activation and function of effector cells such as mast cells, basophils and eosinophils.

19 June 2025 in Pediatric Pulmonology
Verified
Journal Article
Open access
NMNicole Martin
Nicole Martin
ENEdith Nachbaur
Edith Nachbaur
ZSZsolt Szépfalusi
Zsolt Szépfalusi
DKDóra Krikovsky
Dóra Krikovsky
LKLajos Kovács
Lajos Kovács
SGSaskia Gruber
Saskia Gruber
Background: Pediatric lung transplantation is a therapeutic option for children and adolescents with end‐stage lung disease. While it offers a chance to extend survival and improve physical health, the impact on health‐related quality of life (HRQOL) remains understudied. Methods: This observational study aimed to assess HRQOL in pediatric lung transplant recipients using the EuroQol questionnaire and additional self‐designed questions about school, employment, and housing situations. We compared the results to those in children and adolescents with end‐stage lung disease and investigated possible influencing determinants. Patients were included during routine clinical visits, starting at least 2 months post‐transplant. Data collection was from November 2016 to January 2023. Results: The study included 29 pediatric lung transplant recipients aged between 4 and 17 years at the time of first transplantation. Our findings show a good HRQOL after pediatric lung transplantation with a median EuroQol‐Score of 1.0, representing the best possible EuroQol‐Score, and a median visual analog scale (VAS) score of 93 out of 100. Most patients were engaged in employment or education, and they typically lived with their parents. HRQOL was superior to that of pre‐transplant patients with end‐stage lung disease, suggesting a quality of life improvement by lung transplantation. The presence of chronic lung allograft dysfunction (CLAD), a lower age at transplantation, and a longer time since transplantation were associated with lower HRQOL scores. Conclusion: This study underscores the generally favorable HRQOL experienced by pediatric lung transplant recipients.

25 April 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JSJustyna Sieber
Justyna Sieber
NMNicole Martin
Nicole Martin
KSKlara Schmidthaler
Klara Schmidthaler
RGRené Gaupmann
René Gaupmann
EDEleonora Dehlink
Eleonora Dehlink
SGSaskia Gruber
Saskia Gruber
Background/Objectives: Patients with chronic lung diseases, such as cystic fibrosis, were considered a risk group for a severe course of coronavirus disease 2019 at the beginning of the pandemic. However, mounting evidence suggests that this group may not face an elevated risk for a severe SARS-CoV-2 infection. Methods: Here, we present data on the incidence and clinical course of SARS-CoV-2 infections in a single pediatric CF centre in Austria. Clinical variables were analyzed for their potential impact on disease acquisition and severity. A total of 135 young people with CF were assessed from February 2020 until December 2022. Results: Eighty-four patients were infected with SARS-CoV-2, out of which nine patients reported re-infection, resulting in 93 SARS-CoV-2 infections. Most infections, 76/93 (82%), occurred during the period of omicron variant predominance. Higher body mass index and respiratory colonization with Haemophilus influenzae before the beginning of the pandemic were significantly associated with the risk of acquiring SARS-CoV-2 infection. All patients had an uncomplicated COVID-19 course, regardless of the SARS-CoV-2 variant and COVID-19 vaccine status at infection. The most frequent symptoms were rhinitis (53%), fatigue (49%), cephalea (43%), and fever (38%). Neither oxygen therapy nor hospitalization were needed for any of the patients. Lung function parameters (FEV1, FVC, FEF50, LCI), both in the early post-viral as well as late post-viral stages, were not significantly impacted by SARS-CoV-2 infections. No long-term post-COVID-19 effects were reported. Conclusions: Our single-centre experience suggests that the course of SARS-CoV-2 infections in children and adolescents with CF is primarily mild and uncomplicated.

21 May 2026 in Allergy
Verified
Journal Article
Open access
VDVarsha Dwivedi
Varsha Dwivedi
KSKlara Schmidthaler
Klara Schmidthaler
HDHilal Demir
Hilal Demir
JSJustyna Sieber
Justyna Sieber
RGRené Gaupmann
René Gaupmann
ZSZsolt Szepfalusi
Zsolt Szepfalusi
Background: Sublingual allergen immunotherapy (SLIT) is an effective treatment for immunoglobulin (Ig)E‐mediated allergies. Its success is associated with allergen‐specific (s)IgG, which blocks IgE‐mediated mechanisms. Preventive effects of SLIT in children before allergy‐symptom onset remain largely unexplored. Methods: A randomized trial was conducted between October 06, 2017 and December 15, 2022, which included house dust mite (HDM)‐sensitized preschool children (aged 3–5 years) showing no allergy symptoms. They were randomized (2:2 blocks) to HDM‐SLIT (300 index of reactivity/day, Staloral) or placebo solution for 2 years. Children receiving > 4 months of treatment were included in the analysis. Primary objective of the study was to compare the groups for change in major HDM allergen‐Der p 1‐sIgG levels from baseline to end of treatment (EOT). Secondary objectives were to compare longitudinal changes (at 4 and 12 months, and EOT) in the (i) levels of HDM‐sIgG subclasses and ‐sIgE using ImmunoCAP/‐ISAC and/or ELISA (ii) Der p‐reactivity in skin and basophils using skin prick test and basophil activation test (BAT), (iii) sensitization status defined as sIgE‐positivity in skin and/or serum, and (iv) Der p‐sIgE‐blocking activity using inhibition‐BAT. Results: Eighteen children received HDM‐SLIT (mean age = 4.26 ± 0.37 years, eight females) and 15 placebo (mean age = 4.16 ± 0.59 years, nine females). HDM‐SLIT increased Der p 1‐sIgG levels between baseline and EOT versus placebo (effect size = 3.11 [95% CL 1.36–4.82], p = 0.001). Additional changes induced by HDM‐SLIT were: increased levels of HDM‐sIgG 1 and ‐sIgG 4 , no long‐term increase in HDM‐sIgE levels, reduced Der p‐reactivity in skin and basophils ( p values ≤ 0.05), and blunted development of new sensitizations. Sera from HDM‐SLIT treated individuals displayed blocking activity on basophils ( p values ≤ 0.05). Conclusions: Preventive application of HDM‐SLIT in allergy‐prone children induces immunomodulatory effects early during treatment (elevated sIgG levels with blocking activity and reduced effector cell responses), thereby revealing potential to interfere with allergy development. Trial Registration: EudraCT#2016‐002844‐18